43
5
13
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T21512 |
MMP-2/MMP-9 Inhibitor I
|
MMP | Proteases/Proteasome |
MMP-2/MMP-9-IN-1 是一种有效的、具有高选择性和可口服的 IV 型胶原酶 (MMP-9和MMP-2) 抑制剂,对 MMP-9 和 MMP-2具有抑制作用, IC50分别为 0.24 和 0.3 1μM。MMP-2/MMP-9-IN-1 在肿瘤生长和转移的动物模型中展现出口服活性,可用于研究癌症。 | |||
T36712 |
BPHA
MMP-2/MMP-9 Inhibitor II |
MMP | Proteases/Proteasome |
BPHA (MMP-2/MMP-9 Inhibitor II) 是一种有效的、具有选择性和口服活性的抑制剂,对MMP-2、MMP-9 和 MMP-14 具有抑制作用,IC50 分别为 12 nM、16 nM 和 17 nM。BPHA 不抑制 MMP-1、-3 和 -7 (IC50 分别为 974、>1000 和 795 nM)。BPHA 具有抗血管生成和抗肿瘤活性。 | |||
T37726 |
MMP-9 Inhibitor I
|
||
MMP-9 inhibitor I is an inhibitor of matrix metalloproteinase-9 (MMP-9) that is selective over MMP-1 and MMP-13 (IC50s = 5, 1,050, and 113 nM, respectively). It also decreases the activity of TNF-α converting enzyme (TACE) in a dose-dependent manner (IC50 = 0.54 μM). MMP-9 inhibitor I decreases TNF-α secretion stimulated by LPS in BV-2 microglial cells when used at concentrations of 50 and 100 μM. | |||
T37172 |
MMP-9/MMP-13 Inhibitor I
|
||
MMP-9/MMP-13 Inhibitor I 是 MMP-9 和 MMP-13 双重抑制剂,IC50 均为 0.9 nM。MMP-9/MMP-13 Inhibitor I 对 MMP-9/MMP-13 的选择性是其他 MMP 的 20 倍以上。 | |||
T7522 |
GI254023X
GI 254023X |
MMP; Immunology/Inflammation related | Immunology/Inflammation; Proteases/Proteasome |
GI254023X 是MMP9和ADAM10抑制剂,它们的IC50s 分别为 2.5 和 5.3 nM。 | |||
TP1545L1 |
FFAGLDD amine salt
|
Others | Others |
FFAGLDD amine salt 是MMP9选择性裂解肽,用于多柔比星(DOX)的胞浆递送,实现时间和空间可控的缓慢药物递送和释放。 | |||
T72069 |
MMP-9-IN-7
|
||
MMP-9-IN-7抑制前基质金属蛋白酶活化,可用于预防、治疗或改善 MMP9和/或 MMP13介导的综合征。 | |||
T76856 |
Andecaliximab
GS-5745 |
MMP; Virus Protease | Microbiology/Virology; Proteases/Proteasome |
Andecaliximab 是一种靶向基质金属蛋白酶 9 (MMP9) 的重组 IgG4 单克隆抗体。Andecaliximab 在特发性肺纤维化小鼠模型中显示出抗纤维化作用。Andecaliximab 可用于研究胃腺癌和特发性肺纤维化 (IPF) 以及登革热病毒。 | |||
T3560 |
Desmethylanethol trithione
ADT-OH |
VEGFR; Akt | Angiogenesis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Desmethylanethol trithione (ADT-OH) 是合成硫化氢的供体。它利用上调 FADD 诱导细胞凋亡,并对体内黑色素瘤的形成具有一定的抑制作用,可用于研究癌症疾病。 | |||
T77617 |
MMP-9-IN-6
|
MMP | Proteases/Proteasome |
MMP-9-IN-6 是一种 MMP-9 抑制剂,其 IC50 值为50 μM, 具有较好的抗溃疡功效。MMP-9-IN-6 具有潜在的抗肿瘤活性,可用于研究组织重塑、伤口修复和动脉粥样硬化。 | |||
T10597 |
BR351
|
MMP | Proteases/Proteasome |
BR351 is a brain penetrant MMP inhibitor (IC50s: 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13). | |||
T4783 |
JNJ0966
|
MMP | Proteases/Proteasome |
JNJ0966 是高选择性 MMP-9酶原抑制剂,其 IC50=440 nM。 | |||
T10598 |
BR351 precursor
|
Others | Others |
BR351 precursor is a precursor of BR351. BR351 is a brain penetrant MMP inhibitor (IC50s: 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13). | |||
T26720 |
AZD-6605
AZ11920155,AZ-11920155,AZD6605 |
||
AZD6605 is a potent, reversible inhibitor of, MMP2, MMP9, MMP12 and MMP13. | |||
T26104 |
Ro 28-2653
Ro 28 2653,Ro-28-2653,Ro282653 |
||
Ro 28-2653 is a matrix-metalloproteinases (MMPs) inhibitor with high selectivity for MMP2, MMP9 and membrane type 1-MMP. | |||
TP1741L |
Histatin 5 acetate
Histatin 5 acetate (115966-68-2 Free base) |
MMP | Proteases/Proteasome |
Histatin 5 acetate 抑制宿主基质金属蛋白酶 MMP-2 和 MMP-9 的活性,IC50 分别为 0.57 和 0.25 μM。 | |||
TP1545 |
FFAGLDD
|
Others | Others |
FFAGLDD 是 MMP9 选择性切割肽,用于多柔比星 (DOX) 的胞浆递送,实现时间和空间控制的缓慢药物递送和释放。 | |||
TP1498 |
FFAGLDD TFA
|
||
FFAGLDD TFA is an MMP9 selective cleavage peptide, which is used for the cytoplasmic transfer of doxorubicin (DOX) to realize the controlled slow drug delivery and release. | |||
T2009 |
SB-3CT
|
MMP | Proteases/Proteasome |
SB-3CT 是一种可透过血脑屏障的、竞争性的金属蛋白酶MMP-2和MMP-9抑制剂,Ki 分别为 13.9 nM、600 nM。他对明胶酶具有高选择性。它具有神经保护和抗癌作用。 | |||
T16124 |
MMP13-IN-3
|
MMP | Proteases/Proteasome |
MMP13-IN-3 是口服有效的MMP-13选择性抑制剂,IC50为 1 nM,比其他 MMP 的选择性高 1000倍多。MMP13-IN-3在用于骨关节炎方面有研究的价值。 | |||
T27654 |
JG26
JG 26,JG-26 |
MMP; Immunology/Inflammation related | Immunology/Inflammation; Proteases/Proteasome |
JG26 是一种强效的 ADAM17 抑制剂,对 ADAM8、ADAM17、ADAM10 和 MMP-12 均有抑制作用,其 IC50 值分别为 12 nM、1.9 nM、150 nM 和 9.4 nM,可用于研究机体免疫系统。 | |||
T61271 |
MMP2-IN-3
|
MMP | Proteases/Proteasome |
MMP2-IN-3是一种有效的基质金属蛋白酶(MMP-2)抑制剂( IC50 值:31 μM)。MMP2-IN-3 抑制 MMP-9 和 MMP-8 ,其 IC50 分别为 26.6 和 32 μM。 | |||
T14322 |
ARP-100
MMP-2 Inhibitor III |
MMP | Proteases/Proteasome |
ARP-100 (MMP-2 Inhibitor III) 是选择性基质金属蛋白酶MMP-2抑制剂 (IC50=12 nM)。它对 MMP-1 (>50 μM),MMP-3 (4.5 μM),MMP-7 (>50 μM) 和MMP-9 (0.2 μM) 的抑制活性较小。它与 MMP-2 的 S1'口袋相互作用,并在体外对基质胶的侵袭模型中显示抗侵袭特性。 | |||
T12414 |
PF-00356231 hydrochloride
|
MMP | Proteases/Proteasome |
PF-00356231 hydrochloride 是基质金属蛋白酶 MMP-12 的抑制剂,IC50 为 1.4 μM。 | |||
T6885 |
Marimastat
BB2516,马立马司他,KB-R8898,TA2516 |
MMP | Proteases/Proteasome |
Marimastat (BB2516) 是一种血管生成和转移抑制剂,限制血管的生长和生成。它是一种广谱的,具有口服活性的MMPs 抑制剂,有效抑制 MMP-9 , MMP-1, MMP-2, MMP-14, MMP-7,用于癌症的研究。 | |||
T6011 |
Batimastat
巴马司他,BB94 |
MMP | Proteases/Proteasome |
Batimastat (BB94) 是广谱MMP 抑制剂,能够抑制MMP-1 (IC50:3 nM),MMP-2 (IC50:4 nM),MMP-9 (IC50:4 nM),MMP-7 (IC50:6 nM) 和 MMP-3 (IC50:20 nM)。 | |||
T20563 |
PD-166793
PD-166793-0000,PD 166793,PD166793 |
MMP | Proteases/Proteasome |
PD-166793是一种具有口服活性、有效性和选择性的 MMP 抑制剂,对 MMP-2,MMP-3 和 MMP-13 具有抑制作用。PD-166793 在大鼠心力衰竭模型中改善心肌缺血和再灌注损伤。 | |||
T2743 |
Ilomastat
Galardin,GM6001,伊洛马司他 |
MMP | Proteases/Proteasome |
Ilomastat (GM6001) 是广谱的基质金属蛋白酶 (MMP) 抑制剂,可抑制 MMP 的活性,IC50值分别为 1.5 nM (MMP-1),1.1 nM (MMP-2),1.9 nM (MMP-3),0.5 nM (MMP-9),对人皮肤成纤维细胞胶原酶 (MMP-1) 的Ki=为 0.4 nM。 | |||
T12539 |
Prinomastat hydrochloride
KB-R9896 hydrochloride,AG3340 hydrochloride |
MMP | Proteases/Proteasome |
Prinomastat hydrochloride is a orally active inhibitor of metalloproteinase (MMP)(MMP-1, MMP-3 and MMP-9 with IC50s of 79, 6.3 and 5.0 nM , respectively),with Antitumor avtivity. | |||
T12539L |
Prinomastat
KB-R9896,普啉司他,AG3340 |
MMP | Proteases/Proteasome |
Prinomastat inhibits MMP-2, MMP-3 and MMP-9 (Kis: 0.05 nM, 0.3 nM and 0.26 nM, respectively). Prinomastat crosses the blood-brain barrier. It also has antitumor activity. Prinomastat is a broad-spectrum, potent, orally active metalloproteinase inhibitor ( | |||
T28146 |
ND-336
ND336,ND-336 hydrochloride,ND 336 |
||
ND-336 is a highly selective inhibitor ofMMP-2, MMP-9 and MMP-14. ND-336 accelerates diabetic wound healing by lowering inflammation and by enhancing angiogenesis and re-epithelialization of the wound. | |||
T10461 |
Batimastat sodium salt
BB-94 sodium salt |
MMP | Proteases/Proteasome |
Batimastat (BB-94) sodium salt is a broad-spectrum MMP inhibitor (IC50s: 3, 4, 4, 6, and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7, and MMP-3). | |||
T12082 |
MMP3 inhibitor 1
|
MMP | Proteases/Proteasome |
MMP3 inhibitor 1 is a potent and highly selective inhibitor of MMP-3 (IC50 of 1 nM). | |||
T16986 |
Tanomastat
BAY 12-9566 |
MMP | Proteases/Proteasome |
Tanomastat is an orally bioavailable and non-peptidic biphenyl matrix metalloproteinases inhibitor. For MMP-2, MMP-3, MMP-9, MMP-13 the Ki values are 11, 143, 301, and 1470 nM respectively. | |||
T38800 |
MMPI-1154
|
||
MMPI-1154 is a highly promising imidazole-carboxylic acid (ICA) MMP-2 inhibitor (IC 50 = 6.6 μM) with excellent cardio-cytoprotective properties. It is specifically designed for the study of acute myocardial infarction. Additionally, MMPI-1154 exhibits significant inhibitory effects on MMP-13, MMP-1, and MMP-9 activities with IC 50 values of 1.8 μM, 10 μM, and 13 μM, respectively. | |||
T17201 |
UK 356618
|
MMP | Proteases/Proteasome |
UK 356618 is a potent and selective inhibitor of matrix metalloprotease-3 (IC50: 5.9 nM). | |||
T13358 |
XL-784
|
MMP | Proteases/Proteasome |
XL-784 is a selective inhibitor of matrix metalloproteinases (MMP)(IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1,MMP-2,MMP-3,MMP-8,MMP-9,MMP-13,respectively). | |||
T13357 |
XL-784 free base
|
Others | Others |
XL-784 free base is a selective inhibitor of matrix metalloproteinases (MMP), (IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1,MMP-2,MMP-3,MMP-8,MMP-9,MMP-13,respectively). | |||
T22685 |
CP-471474
CP 471474 |
Others | Others |
Broad spectrum MMP inhibitor (IC<sub>50</sub> values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice. | |||
T13249 |
UK-370106
|
MMP | Proteases/Proteasome |
UK-370106 is a potent and highly selective inhibitor of MMP-3 with IC50 of 23 nM and MMP-12 with IC50 of 42 nM, and potently inhibits cleavage of [3H]-fibronectin by MMP-3 (IC50: 320 nM). | |||
T31063 |
CP-544439
UNII-516DO4KL5R |
||
CP-544439 is an inhibitor of matrix metalloproteinase-13, which has an effect on adipose tissue development. | |||
T36492 | CMC2.24 | ||
CMC2.24 (TRB-N0224) is an orally active tricarbonylmethane agent that demonstrates effectiveness in inhibiting Ras activation and the downstream effector ERK1/2 pathway, thus effectively combating pancreatic tumor formation in mice. Additionally, CMC2.24 exerts potent inhibitory effects on zinc-dependent MMPs, with IC50s ranging from 2.0-69 μM. Furthermore, CMC2.24 aids in alleviating the progression of osteoarthritis by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis throug... | |||
T28985 |
TMI-1
WAY-171318 |
Apoptosis; MMP | Apoptosis; Proteases/Proteasome |
TMI-1 (WAY-171318) 是一种有效的抑制剂,用于抑制去整合素金属酶17 (ADAM17) 和其他基质金属蛋白酶MMPs。TMI-1 能够有效地抑制LPS 诱导的人原代单核细胞和人全血中TNF-α的分泌。TMI-1 在三阴性 (TN) 和过度表达ERBB2的乳腺肿瘤细胞系中选择性地诱导Caspase 依赖的细胞凋亡。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3860 |
Isoliquiritin apioside
|
MMP; p38 MAPK; NF-κB | MAPK; NF-κB; Proteases/Proteasome |
Isoliquiritin apioside 可抑制癌细胞和内皮细胞的侵袭和血管生成,显著降低 PMA 诱导的MMP9活性增加,并抑制 PMA 诱导的MAPK 和NF-κB 活化。 | |||
T3414 |
Morroniside
莫诺苷,奎宁树 |
Apoptosis; MMP; Pyroptosis | Apoptosis; Immunology/Inflammation; Proteases/Proteasome |
Morroniside 通过抑制神经元凋亡和 MMP9/2 的表达从而发挥神经保护作用,可作为 db/db 小鼠肝脏炎症反应和脂质代谢的调节剂。它通过抑制高血糖和氧化应激表现出对糖尿病肾损伤和人脐静脉内皮细胞的保护作用。 | |||
T4S21320 |
ISOGINKGETIN
异银杏素,4',4'''-Dimethylamentoflavone,异银杏双黄酮 |
MMP; Others | Others; Proteases/Proteasome |
ISOGINKGETIN (4',4'''-Dimethylamentoflavone) 是一种MMP9抑制剂,也是一种Pre-mRNA Splicing 抑制剂。 | |||
T3850 |
Luteolin 7-O-glucuronide
Luteolin-7-glucuronide,木犀草素-7-O-葡萄糖醛酸苷 |
MMP | Proteases/Proteasome |
Luteolin 7-O-glucuronide (Luteolin-7-glucuronide) 是一种自由基清除剂,能够抑制基质金属蛋白酶的活性,其对 MMP-1,MMP-3,MMP-8,MMP-9,MMP-13的IC50值分别为 17.63,7.99,11.42,12.85,0.03 μM。 | |||
T5S1026 |
Apigenin-7-glucuronide
Apigenin 7-O-glucuronide,芹菜素-7-葡萄糖醛酸 |
MMP | Proteases/Proteasome |
Apigenin-7-glucuronide (Apigenin 7-O-glucuronide) 能够抑制基质金属蛋白酶的活性,其对 MMP-3 (IC50:12.87 μM),MMP-8 (IC50:22.39 μM),MMP-9 (IC50:17.52 μM),MMP-13 (IC50:0.27 μM)。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01919 |
MMP-9 Protein, Mouse, Recombinant
matrix metallopeptidase 9,Clg4b,MMP-9<... |
Mouse | HEK293 Cells |
MMP-9 Protein, Mouse, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 78.4 kDa and the accession number is P41245-1. | |||
TMPY-01248 |
MMP-9 Protein, Human, Recombinant
MANDP2,MMP-9,GELB,matrix metallopeptidase ... |
Human | HEK293 Cells |
MMP-9 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 76.3 kDa and the accession number is P14780. | |||
TMPY-00888 |
MMP-9 Protein, Human, Recombinant (His)
MANDP2,CLG4B,GELB,matrix metallopeptidase 9,MMP... |
Human | HEK293 Cells |
MMP-9 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 77.7 kDa and the accession number is P14780. | |||
TMPK-00368 |
MMP-9 Protein, Human, Recombinant (His & Avi), Biotinylated
Gelatinase B,MMP-9,MANDP2,CLG4B,GELB |
Human | HEK293 Cells |
Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14. MMP-9 Protein, Human, Recombina... | |||
TMPK-00503 |
MMP-9 Protein, Cynomolgus, Recombinant (His)
MMP-9,CLG4B,Gelatinase B,MANDP2,GELB |
Cynomolgus | HEK293 Cells |
Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14. MMP-9 Protein, Cynomolgus, Reco... | |||
TMPK-00367 |
MMP-9 Protein, Human, Recombinant (His & Avi)
MANDP2,CLG4B,Gelatinase B,GELB,MMP-9 |
Human | HEK293 Cells |
Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14. MMP-9 Protein, Human, Recombina... | |||
TMPJ-00957 |
MMP-9 Protein, Mouse, Recombinant (His)
Matrix metalloproteinase-9,92 kDa gelatina... |
Mouse | HEK293 Cells |
Matrix metalloproteinases are a family of zinc and calcium dependent endopeptidases with the combined ability to degrade all the components of the extracellular matrix. MMP-9 (gelatinase B) can degrade a broad range of substrates including gelatin, collagen types IV and V, elastin and proteoglycan core protein. It is believed to act synergistically with interstitial collagenase (MMP1) in the degradation of fibrillar collagens as it degrades their denatured gelatin forms. MMP-9 is produced by ker... | |||
TMPK-00946 |
EFEMP1 Protein, Human, Recombinant (His)
MLVT,S1-5,Fibulin 3,FBNL,fibrillin-like,MGC111353,FBLN3,FBNL... |
Human | HEK293 Cells |
Transversalis fascia EFEMP1, TIMP3 and ELN expressions were decreased, but MMP9 expression was increased in IH patients compared with controls. In IH patients, EFEMP1 was not correlated with TIMP3, but positively correlated with ELN and negatively correlated with MMP9; TIMP3 negatively correlated with MMP9, but positively correlated with ELN.In addition, EFEMP1 suppressed L929 cell migration and invasion. EFEMP1 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with N-His ... | |||
TMPK-01082 |
EFEMP1 Protein, Mouse, Recombinant (His)
EFEMP1,MTLV,MGC111353,MLVT,S1-5,DHRD,FBNLFLJ35535,fibrillin-... |
Mouse | HEK293 Cells |
Transversalis fascia EFEMP1, TIMP3 and ELN expressions were decreased, but MMP9 expression was increased in IH patients compared with controls. In IH patients, EFEMP1 was not correlated with TIMP3, but positively correlated with ELN and negatively correlated with MMP9; TIMP3 negatively correlated with MMP9, but positively correlated with ELN.In addition, EFEMP1 suppressed L929 cell migration and invasion. EFEMP1 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with N-His ... | |||
TMPH-01316 |
ECM1 Protein, Human, Recombinant (GST & His & Myc)
Extracellular matrix protein 1,ECM1,Secretory component p85 |
Human | E. coli |
Involved in endochondral bone formation as negative regulator of bone mineralization. Stimulates the proliferation of endothelial cells and promotes angiogenesis. Inhibits MMP9 proteolytic activity. ECM1 Protein, Human, Recombinant (GST & His & Myc) is expressed in E. coli expression system with N-10xHis-GST and C-Myc tag. The predicted molecular weight is 52.4 kDa and the accession number is Q16610. | |||
TMPK-01034 |
SEMA4B Protein, Mouse, Recombinant (His)
SEMA4B,SemC,Semaphorin-C,MGC131831,Semaphorin-4B,KIAA1745,SE... |
Mouse | HEK293 Cells |
Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung cancer (NSCLC) through PI3K-dependent suppression of MMP9 activation. SEMA4B may induce FoxO1 nuclear retention through suppressing PI3K/Akt signaling pathway, which subsequently inhibited cell growth through the direct nuclear target of FoxO1, p21. A role of SEMA4B in suppressing NSCLC growth, besides its role in inhibiting cell metastasis, and highlights SEMA4B as a promising therapeutic target for NSCLC. | |||
TMPH-01297 |
DDR1 Protein, Human, Recombinant (aa 21-417, His)
EDDR1,MCK-10,Epithelial discoidin domain-containing receptor... |
Human | HEK293 Cells |
Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell... | |||
TMPY-02689 |
MMP-3 Protein, Human, Recombinant
STMY,MMP-3,matrix metallopeptidase 3,CHDS6,STMY1,SL... |
Human | E. coli |
Matrix metallopeptidase 3 (abbreviated as MMP3) is also known as stromelysin 1 and progelatinase. MMP3 is a member of the matrix metalloproteinase (MMP) family whose members are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, tissue remodeling, and disease processes including arthritis and metastasis. As a secreted zinc-dependent endopeptidase, MMP3 exerts its functions mainly in the extracellular matrix. This prot... |